Slide 1: Prelim Results for the 12 Months Period Ending 31st December 2021
TM pre|CISION TM pre|CISION Prelim Results for the 12 Months Period Ending 31st December 2021 April 6, 2022 © Avacta Group plc 1
Slide 2: Disclaimer: Important Notice
Disclaimer: Important Notice TM pre|CISION No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accu
Slide 3: Introduction
TM pre|CISION Introduction © Avacta Group plc 3
Slide 4: Today's Presentation Team
Today’s Presentation Team TM pre|CISION Dr Alastair Smith, CEO • Over 16 years experience as a life sciences public company CEO. • Science background with 13 years in academia – established a leading UK biophysics group. • Founded Avacta in 2006. • World class scientific and technical knowledge with
Slide 5: Group Overview
Group Overview TM pre|CISION Diagnostics Division • In-vitro diagnostics company based in Wetherby, UK. • R&D Centre and plc Headquarters. LSE: AVCT • In-house IVD product ````` development pipeline. • Global technology evaluations and partnerships. Therapeutics Division • Clinical stage oncology dr
Slide 6: Preliminary Results for the Period Ended 31st December 2021
TM pre|CISION Preliminary Results for the Period Ended 31st December 2021 © Avacta Group plc 6
Slide 7: Preliminary Results 2021: Income Statement
Preliminary Results for the Year Ending 31st December 2021: Income Statement TM pre|CISION 2021 (£m) 2020 (£m) Revenue 2.94 2.14 Gross profit 2.02 1.18 Research costs (13.48) (9.11) Manufacturing costs (2.14) - Admin costs (8.14) (5.93) Amortisation/Depreciation/SBP (7.34) (4.95) Operating loss (29.
Slide 8: Preliminary Results 2021: Segmental Analysis
Preliminary Results for the Year Ending 31st December 2021: Segmental Analysis TM pre|CISION Diagnostics Therapeutics Animal Health (£m) (£m) (£m) 2021 2020 2021 2020 2021 2020 Income Statement Revenue 0.78 0.52 2.16 1.63 1.60 1.49 Gross profit 0.56 0.20 1.46 0.98 1.10 1.00 Research costs (3.67) (2.
Slide 9: Preliminary Results 2021: Cash Flow and Balance Sheet
Preliminary Results for the Year Ending 31st December 2021: Cash Flow and Balance Sheet TM pre|CISION 2021 (£m) 2020 (£m) Operating activities (21.52) (14.07) Working capital (1.13) 0.73 Tax and interest 2.15 2.70 Investment (1.31) (21.90) Financing 0.23 51.65 Net cash (outflow)/inflow (21.58) 19.11
Slide 10: Therapeutic Division Update
TM pre|CISION Therapeutic Division Update Improving the lives of people with cancer through tumour-targeted therapies © Avacta Group plc 10
Slide 11: Tumour Targeted Activation of Cancer Therapies
pre|CISIONTM Tumour Targeted Activation of Cancer Therapies pre|CISION TM What is pre|CISIONTM? “FAP High” tumours • pre|CISION is a highly specific substrate for fibroblast activation protein-a (FAPa), an extracellular enzyme that is upregulated in most solid tumours. • pre|CISION prevents chemothe
Slide 12: The preCISION Platform in Detail
The pre|CISIONTM Platform in Detail pre|CISION TM Reducing the side-effects of chemotherapy by tumour-specific activation AVA6000 Active Doxorubicin Tumour Microenvironment Cancer cells Naïve T cells 2 FAPa Macrophage B cells Fibroblast FAPa +ve fibroblasts and cancer cells © Avacta Group plc 12
Slide 13: AVA6000 preCISION Pro-doxorubicin
AVA6000 pre|CISIONTM Pro-doxorubicin pre|CISION TM AVA6000 addresses the safety issues of a $1bn generic chemotherapy Targeting of Active Chemotherapy to Tumour Tissue in a Mouse Model Tumour/Heart Ratio ~18:1 Tumour/Heart Ratio ~1:1 Standard Doxorubicin Doxorubicin (AVA6000) (6x higher dose) Public
Slide 14: AVA6000 preCISION Pro-doxorubicin: Market Opportunity
AVA6000 pre|CISIONTM Pro-doxorubicin pre|CISION TM AVA6000 market opportunity • Doxorubicin has been a standard of care treatment for advanced soft tissue sarcoma (ASTS) for 40 years. • Its use is limited by serious dose limiting toxicities such as cardio-toxicity and myelosuppression. • Despite thi
Slide 15: The Wider preCISION Pro-drug Opportunity
The Wider pre|CISIONTM Pro-drug Opportunity TM pre|CISION pre|CISIONTM can be widely applied to a range of other chemotherapies in a market worth $56.5B with CAGR of 11.50% driven by increased cancer detection rates Example: Velcade • Bortezomib (Velcade, Takeda Pharmaceuticals) had annual • Ideal f
Slide 16: AVA6000 Phase I Design and Anticipated Timeline
AVA6000 Phase I Design and Anticipated Timeline pre|CISION TM 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase Ia - Dose Escalation Phase Ib - Dose Expansion Phase 1a Phase 1b • Objective: Assess safety and • Objective: Confirm safety and tolerability tolerability of AVA6000; determine of AV
Slide 17: Phase 1a Dose Escalation Study
Phase 1a Dose Escalation Study pre|CISION TM • Up to six clinical trial sites in UK: • Active sites: St James’ Leeds, The Royal Marsden, London and The Christie, Manchester. • The Beatson, Glasgow now open and screening patients. • UK sites Q2: The Freeman, Newcastle and Western Park, Sheffield. • S
Slide 18: Phase 1a Dose Escalation Study: Objectives
Phase 1a Dose Escalation Study pre|CISION TM Primary Objectives: • To evaluate the safety and tolerability of AVA6000. • To determine the maximum-tolerated dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) for the dose expansion phase. Secondary Objectives: • To characterise the pharmacokinetics
Slide 19: Key Partnerships Update (2021)
Key Partnerships Update (2021) TM pre|CISION Life Sciences • (2018) multi-target agreement to develop • (2020) JV (AffyXell) developing next generation Affimer® therapeutics in several disease areas. cell and gene therapies incorporating Affimer • (2020) partnership expanded to include proteins. Ava
Slide 20: Therapeutic Division Relocation
Therapeutic Division Relocation pre|CISION TM • Co-location of Avacta’s Research & Development organisations into a single location in state of the art laboratories and office space in Scale Space, White City. • Imperial College’s White City campus in West London is bringing together scientific rese
Slide 21: Non-Executive Director Appointments
Non-Executive Director Appointments pre|CISION TM Christina Coughlin, MD Mark A. Goldberg, MD Non Executive Director Non Executive Director • Chief Executive Officer of • Medical oncologist and CytoImmune Therapeutics. hematologist and a • Dr. Coughlin joined biotechnology executive. CytoImmune from
Slide 22: Diagnostics Division Update
TM pre|CISION Diagnostics Division Update Powerful diagnostics to improve health and well-being for all © Avacta Group plc 22
Slide 23: Key Trends in Diagnostics
Key Trends in Diagnostics pre|CISION TM • Decentralised (“Point-of-care”) and Home-testing: • Chronic disease monitoring; • Health screening driving early intervention; • Health/well-being monitoring – in tandem with digital health monitoring (“wearables”); • Increasing availability of PoC molecular
Slide 24: Avacta Diagnostics
Avacta Diagnostics pre|CISION TM Uniquely positioned UK diagnostics company with proprietary Affimer immunodiagnostics technology to address key unmet market needs and drive competitive advantage and shareholder value • Maintain a strong decentralised (Point of care) testing focus. • Serve the profe
Slide 25: AffiDX SARS-CoV-2 Antigen Rapid Test
AffiDX® SARS-CoV-2 Antigen Rapid Test TM pre|CISION • Consumer self-testing CE mark (in partnership with Medusa19) in December 2021 as Omicron variant emerged. – > 30 mutations difference between Omicron (BA.1) and Delta. – > 30 mutations difference between Omicron and BA.2. • AffiDX SARS-CoV-2 anti
Slide 26: Broader Diagnostics Product Vision
Broader Diagnostics Product Vision pre|CISION TM Infectious Diseases Chronic Disease / Treatment Monitoring ▪ Respiratory diseases (e.g. COVID19, Flu A/B) ▪ Cardiac disease (e.g. heart failure, AMI, stroke) ▪ Sexually transmitted diseases ▪ Cancer markers ▪ Sepsis/Bloodstream infections ▪ Diabetes (
Slide 27: Summary
Summary TM pre|CISION 2020/21 was a transformational period with the transition of the Therapeutics Division to clinical stage and the launch of the first Affimer® IVD product Therapeutics – the key value driver for the Group • AVA6000 pro-doxorubicin: Conducting Phase 1a dose escalation study (in U
Slide 28: Broker and Nominated Adviser, IR Contacts
TM pre|CISION Broker and Nominated Adviser Stifel Nicolaus Europe Limited Nicholas Moore / Nick Adams / Fred Walsh / Nicholas Harland nicholas.moore@stifel.com nick.harland@stifel.com nick.adams@stifel.com fred.walsh@stifel.com www.stifel.com Tel: +44 (0) 207 710 7600 FTI Consulting (Financial Media